Table 2.

Most common adverse events associated with dinutuximab beta therapy observed in our patient cohort.

Adverse event	Grading	Cycle 1 (7×)	Cycle 2 (6×)	Cycle 3–5 (18×)
Capillary leak syndrome	II	4	4	3
	III	3	–	–
Pain	I + II	1	2	3
Nausea/vomiting/anorexia/diarrhea	I + II	3	2	6
Ataxia/gait disturbance	III	1	–	–
Dysarthria	II	2	–	–
Allergic manifestations	I + II	3	2	5
Hepatopathia	I + II	6	5	12
Anemia	I + II	3	6	16
	III	4	–	–
Thrombocytopenia	I + II	1	3	3
	III + IV	3	1	–
Hypoalbuminemia	I + II	5	6	15
	III	2	–	–